ScholarWorks@Korea University College of Medicine: Choi, Kyung Mook

Detailed Information

Choi, Kyung Mook(최경묵)

Guro Hospital (Department of Endocrinology and Metabolism, Guro Hospital)

Research Area: Sarcopenic Obesity, Organokines - Adipokines, myokines, and hepatokines, Diabetes and Metabolic Syndrome

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

metabolic syndrome:15||type 2 diabetes:14||Obesity:14||Metabolic syndrome:14||Diabetes mellitus:13||insulin resistance:13||Inflammation:12||Korea:11||Type 2 diabetes:10||Diabetes mellitus, type 2:10||Sarcopenia:9||Atherosclerosis:8||Insulin resistance:7||Practice guideline:7||sarcopenia:7||Adipokines:7||Nonalcoholic fatty liver disease:6||adiponectin:6||variability:6||Hypoglycemic agents:6||obesity:6||Dementia:5||adipokine:5||hypertension:5||ER stress:5||s disease:5||atherosclerosis:4||diabetes:4||inflammation:4||Glucose:4||AMPactivated protein kinase:4||Creactive protein:4||당뇨병:4||Adiponectin:4||type 2:4||Insulin:4||nonalcoholic fatty liver disease:4||Korean:4||prevalence:4||Cardiovascular diseases:4||Heart failure:4||Nonalcoholic fatty liver disease:4||Hepatokine:4||chronic kidney disease:3||FetuinA:3||Parkinson&apos:3||pulse wave velocity:3||Mortality:3||Muscle:3||Cardiovascular disease:3||Apoptosis:3||Pulse wave velocity:3||Cholesterol:3||diabetes mellitus:3||mortality:3||positron emission tomography:3||AMPK:3||Positron emission tomography:3||aging:3||LDL:3||visfatin:3||dementia:3||Arterial stiffness:3||Type 2 diabetes mellitus:3||Clinical practice guideline:3||Selenoprotein P:3||Alzheimer&apos:3||Menopause:2||muscle strength:2||Atorvastatin:2||nonalcoholic fatty liver disease:2||nonalcoholic fatty liver:2||Dipeptidyl peptidaseIV inhibitors:2||BCG:2||Insulin Resistance:2||Nonalcoholic fatty liver:2||osteoporosis:2||peroxisome proliferatoractivated receptors:2||pheochromocytoma:2||Adiposity:2||prehypertension:2||Dyslipidemias:2||Oral hypoglycemic agents:2||Blood pressure:2||Body composition:2||estimated glomerular filtration rate:2||Body mass index:2||resistin:2||Efficacy:2||rosiglitazone:2||Glycemic variability:2||Elderly:2||Body size phenotype:2||Leptin:2||gammaglutamyl transferase:2||Vascular stiffness:2||Leukocyte cellderived chemotaxin 2:2||Endothelial cells:2||DPP4 inhibitor:2||Alzheimer disease:2||stroke:2||Diabetes:2||adipocyte:2||Fasting plasma glucose:2||type 2 diabetes mellitus:2||Statin:2||urine dipstick test:2||vascular dementia:2||Risk factors:2||Hepatokines:2||visceral obesity:2||Aging:2||Metformin:2||HydroxymethylglutarylCoA reductase inhibitors:2||impaired glucose tolerance:2||Salsalate:2||interleukin6:2||Sarcopenic obesity:2||biomarker:2||blood pressure:2||body composition:2||brain atrophy:2||Hypertension:2||Muscle mass:2||cJun Nterminal kinase:2||비만:2||Muscle strength:2||Skeletal muscle:2||Fibroblast growth factor 21:2||Frailty:2||metabolic syndrome X:2||cardiovascular disease:2||충수주위농양:2||cardiovascular mortality:2||HIF1:1||HMGCoA reductase inhibitor:1||Health Insurance Review &:1||Health behavior:1||Heart rate:1||Heart rate variability:1||Hematologic parameters:1||Hepatic steatosis:1||Highsensitivity Creactive protein:1||Human umbilical vein endothelial cells:1||Hyperaldosteronism:1||Hyperprolactinemia:1||Hyperthyroidism:1||Hypertriglyceridemia:1||Hyperuricemia:1||Hypoglycemia:1||Hypokalemia:1||Hypopituitarism:1||Hypothyroidism:1||Incidence:1||Insulin resistance syndrome:1||Intraabdominal fat:1||Intraoperative parathyroid hormone assay:1||Iodine:1||Korea National Health and Nutrition Examination Survey VI:1||Korean National Health Insurance Corporation:1||Korean National Health and Nutrition Examination Survey:1||Korean National Health and Nutrition Survey:1||Koreans:1||Lcarnitine:1||LDSD:1||LIPOAPOPTOSIS:1||Lasers:1||Left ventricular hypertrophy:1||Life style:1||Lifestyle intervention:1||Lifestyle modification:1||Lipoproteins:1||Lisinopril:1||Liver:1||Liver cirrhosis:1||Low income:1||Low skeletal muscle mass:1||Lowdensity lipoprotein cholesterol:1||MHO:1||Malignant pleural effusion:1||Meal frequency:1||Medical cost 대상 및 방법1. 대상 본 연구는 1994년 12월 1일부터 2002년 12월 31일까지 당뇨병을 주 또는 부상병으로 건강보험심사평가원에 1회 이상 청구된 3:1||Metabolic health:1||Metabolic risk factors:1||Metabolically abnormal but normal weight:1||Metabolically healthy but obese:1||Metrnl:1||Midlife:1||Monotherapy:1||Muscle development:1||Muscles:1||Muscular atrophy:1||Myokines:1||NacetylDGlucosaminidase:1||N/A:1||NAFLD:1||NF kappa B:1||NIDDM:1||NONALCOHOLIC FATTY LIVER DISEASE:1||National survey:1||Neurohypophysis:1||NonHDL cholesterol:1||OLETF:1||OLETF rat:1||Obesity metabolism:1||Omentin1:1||Osteoporosis:1||Osteoporotic fractures:1||Oxidative stress:1||PLASMALEVELS:1||Pain:1||Paraganglioma:1||Parathyroid carcinoma:1||Pathophysiology:1||Periappendiceal abscess:1||Peripheral artery disease:1||Pheochromocytoma:1||Phosphodiesterase inhibitor:1||Pituitary stalk:1||Pooled cohort risk scores:1||Poorly differentiation攀접수일자: 2002년 2월 5일통과일자: 2002년 2월 25일:1||Prediabetic state:1||Prevalence:1||Primary amenorrhea:1||Proinflammatory reactions:1||Progranulin:1||Proliferatoractivated receptorgamma:1||Protectin DX:1||Proteinuria:1||RAGE:1||REPUBLIC OF KOREA:1||Radioiodine ablation:1||Real time continuous glucose monitoring system:1||Receptors:1||Renal function:1||Republic of Korea:1||Resolvin D1:1||Risk assessment:1||Rokitansky syndrome:1||SARCOPENIA:1||SARCOPENIC OBESITY:1||SOLUBLE RECEPTOR:1||SWS study:1||Salicylate:1||Sclerostin:1||Selfmonitoring blood glucose:1||Sesn2:1||Sestrin2:1||Sestrin2 protein:1||Sex difference:1||Skeletal:1||Skeletal muscle mass index:1||Sleep apnea, obstructive:1||Sleep duration:1||Sodium intake:1||Stable angina pectoris:1||Steatosis:1||Stroke:1||Subclinical Atherosclerosis:1||Subcutaneous fat:1||Sulfonylurea:1||Syndrome X:1||TNFa:1||TNFalpha:1||Telemedicine:1||Telmisartan:1||The Korean National Health Insurance Corporation:1||Therapeutics:1||Thiazolidinediones:1||Thyroid:1||Thyroid neoplasms:1||Thyroid papillary carcinoma:1||Thyroidstimulating hormone:1||Transmural internal drainage:1||Triglyceride:1||Triglycerideglucose index:1||Triglycerides:1||Type 1 Diabetes mellitus:1||Type 1 diabetes:1||Type 2:1||Type 2 diabetic rats:1||Type2 diabetes mellitus:1||VASCULAR INFLAMMATION:1||VEGF:1||VISCERAL OBESITY:1||Valsartan:1||Variability:1||Vascular adhesion molecules:1||Vascular inflammation:1||Visceral fat:1||Visittovisit:1||Vitamin D:1||WHO 2h criteria:1||Waist circumference:1||Waisttohip ratio:1||Wessely and Powell score:1||Wnt pathway:1||abdominal:1||abdominal fat computed tomography:1||abdominal obesity:1||acutephase protein:1||acylCoA oxidase:1||adipocyte fatty acidbinding protein:1||adipocytokines:1||adolescents:1||adrenocortical tumor:1||aged:1||albuminuria:1||allout exercise:1||aminotransferase:1||anemia:1||angiotensin II type 1 receptor blockers:1||anklebrachial pressure index:1||antiobesity agents:1||antithyroid drug:1||apoptosis:1||autoimmune type 1 diabetes mellitus:1||beta oxidation:1||betaAminoisobutyric acid:1||big data:1||blood glucose:1||body weight:1||bone density:1||brainstem:1||brown:1||cJun Nterminal kinases:1||cardiac risk factors and prevention:1||cardiometabolic disease:1||cardiometabolic disorders:1||cardiovascular disease (CVD):1||carotid intima media thickness:1||children:1||chronic disease:1||clinical trial:1||cognition:1||cognitive decline:1||continuous glucose monitoring:1||coronary artery disease:1||crosssectional study:1||crosssectional survey:1||cytokine:1||democratic people&apos:1||depression:1||diabetes mellitus nephropathy:1||diabetic nephropathy:1||diet:1||disease:1||dyslipidemia:1||elderly:1||endstage kidney disease:1||endoplasmic reticulum stress:1||energy metabolism:1||epidemiology:1||esRAGE:1||exercise:1||factor analysis:1||fat distribution:1||fatty acid:1||fatty liver disease:1||fenofibrate:1||ferritin:1||fetuinA:1||fiber:1||fibroblast growth factor (FGF) 21:1||fracture:1||frailty:1||fructosamine:1||gammaglutamyltransferase:1||geriatric medicine:1||gestational diabetes mellitus:1||ghrelin:1||gingko:1||glucagonlike peptide1:1||glucose:1||glucose tolerance:1||glucose variability:1||glycaemic control:1||glycation:1||glycemic index:1||glycemic load:1||glycemic variability:1||glycoproteome:1||gout:1||gray matter:1||gut hormones:1||health disparity:1||heart failure:1||hemoglobin:1||hepatic steatosis index:1||high carbohydrate:1||highnormal blood pressure:1||highsensitivity Creactive protein:1||hyperglycaemia:1||hyperlipidemia:1||hyperparathyroidism:1||hyperthyroidism:1||hypertriglyceridaemia:1||hyperuricemia:1||hypothalamus:1||insulitis:1||interleukin 6:1||interleukin10:1||internet:1||irisin:1||isolated diastolic hypertension:1||isolated systolic hypertension:1||lactate:1||lean body mass:1||leukocyte telomere length:1||lipid profile:1||lipocalin2:1||lipoprotein:1||liver steatosis:1||lobeglitazone:1||low muscle mass:1||melatonin:1||metabolic disease:1||metabolic diseases:1||metabolic risk factors:1||microalbuminuria:1||middle aged women:1||mitochondria:1||morbidity:1||mouse:1||muscle mass:1||myocardial infarction:1||myokines:1||night blood pressure:1||nonobese:1||obstructive sleep apnea:1||occupational health:1||older adults:1||older people:1||omega3:1||omentin1:1||oral glucose tolerance test:1||paraganglioma:1||paragangliomas:1||parathyroid adenoma:1||pathophysiology:1||peroxisome proliferatoractivated receptor delta:1||peroxisome proliferatoractivated receptoralpha:1||polycystic ovary syndrome:1||preventive medicine:1||probucol:1||proteinuria:1||proximal tubule cell:1||public health:1||pulse wave:1||quality of life:1||radioactive iodine treatment (RAI treatment):1||radioiodine ablation:1||randomized controlled trial:1||randomized trial:1||receiver operating characteristic curve analysis:1||recur:1||retrospective cohort study:1||risk factors:1||s dementia:1||s republic of korea:1||sFLT1:1||sRAGE:1||sarcopenic obesity:1||short sleep duration:1||sialic acid:1||sitagliptin:1||skeletal:1||skeletal muscle:1||skeletal muscle mass:1||sleep:1||sleep disordered breathing:1||sleep duration:1||socioeconomic status:1||streptozotocin:1||systemic inflammation:1||tea:1||teneligliptin:1||thiazolidinediones:1||thyroid cancer:1||thyroid function:1||thyroidectomy:1||total cholesterol:1||treadmill running:1||triple therapy:1||tumor necrosis factor:1||tumor necrosis factor alpha:1||type 2 diabetic nephropathy:1||unfolded protein response:1||vascular:1||vascular endothelial growth factor:1||vascular inflammation:1||velocity of lactate threshold:1||visceral fat:1||vitamin D:1||vitamin Dbinding protein:1||waist circumference:1||weight loss:1||white blood cell count:1||zz:1||갑상선:1||갑상선 유두암:1||고중성지방혈증:1||급성 충수염:1||급성충수염:1||내부 배액술:1||내시경:1||노인:1||다발성 부신경절종:1||당뇨병성 케톤산증:1||대사증후군:1||대장 내시경:1||렙틴:1||메산지움:1||배액술:1||복부 비만:1||복부비만:1||부신기능부전:1||부신피질암:1||아디포넥틴:1||아디포카인:1||운동:1||음주:1||인슐린 저항성:1||제2형 당뇨병:1||중년기 여성:1||프로인슐린:1||혈압:1||혈청지질. 혈당:1||흉막전이:1||2DE:1||흡연:1||547명의 환자를 대상으로 2003년도의 당뇨병성 족부질환의 발생률과 의료비용을 알아보고자 하였다. 연령군은 연말 기준으로 45세 미만:1||587:1||647명의 환자 중 사망자와 기존 유병자를 제외한 3:1||911:1||ADA fasting criteria:1||AMPactivated protein kinases:1||AMPKactivated protein kinase:1||ANGPTL3:1||ANGPTL8:1||ASSOCIATION:1||ATHEROSCLEROSIS:1||Abdominal fat:1||Abdominal obesity:1||Acute Myocardial Infarction:1||Acute appendicitis:1||Acute coronary syndrome:1||Adipocyte fatty acid binding protein:1||Adipose tissue:1||Adrenergic beta3 receptor agonists:1||Aged:1||Albuminuria:1||Aldosterone receptor blocker:1||Aldosteronism:1||Allcause mortality:1||Angiopoietinlike protein 4:1||Angiotensinconverting enzyme insertion/deletion polymorphism:1||Anthropometric index:1||Antioxidant:1||Antipsychotic agents:1||Antithyroid agents:1||Appendicular lean mass:1||Aspirin resistance:1||Assessment Service:1||Atherogenic dyslipidemia:1||Autophagy:1||Beraprost:1||Blood glucose selfmonitoring:1||Body fat composition:1||Body size phenotypes:1||Body weight:1||Bone muscle interaction:1||Brain atrophy:1||BuddChiari syndrome:1||CREACTIVE PROTEIN:1||C1q/TNFRelated Protein 9:1||C1q/tumor necrosis factorrelated protein3:1||CARDIOMETABOLIC DISEASE:1||CHOP:1||CRP:1||Cardiac autonomic dysfunction:1||Cardiocerebrovascular disease:1||Cardiometabolic risk factors:1||Cardiomyocyte:1||Cardiomyocytes:1||Cardiovascular benefit:1||Casecontrol studies:1||Cell adhesion molecules:1||Cellular phonne:1||Chemerin:1||Children:1||Chronic kidney disease:1||Cilostazol:1||Clinical practice guidelines:1||Cohort:1||Cohort studies:1||Colon cancer:1||Colonoscopy:1||Combination therapy:1||Community networks:1||Comorbidity:1||Computed tomography:1||Coronary artery calcification:1||Coronary artery disease:1||DHEA:1||DHEAS:1||DM nephropathy:1||Delayed puberty:1||Dementia, vascular:1||Diabetes complications:1||Diabetes mellitus Glucose variability:1||Diabetic foot ulcer:1||Diabetic nephropathies:1||Diabetic nephropathy:1||Diagnosis:1||Differentiated thyroid cancer:1||Dipeptidyl peptidase4 inhibitor:1||Dipeptidyl peptidase4 inhibitors:1||Dipeptidylpeptidase IV inhibitors:1||Disability incidence:1||Disease management:1||ENDOGENOUS SECRETORY RAGE:1||ENDOTHELIAL FUNCTION:1||EQVAS:1||ER STRESS:1||Elderly Koreans:1||Endstage renal disease:1||Endoplasmic reticulum stress:1||Endothelium:1||Epidemiology:1||Eplerenone:1||Ezetimibe:1||F18fluorodeoxyglucose positron emission tomography:1||FAM19A5:1||FTO polymorphism:1||Fasting blood glucose:1||Fasting plasma glucose variability:1||Fatigue:1||Fatigue scale:1||Fatty acids:1||Fatty liver:1||Framingham risk score:1||Fulminant:1||Gproteincoupled 40:1||GFR:1||GLYCATION ENDPRODUCTS:1||GLYCEMIC CONTROL:1||Gammaglutamyltransferase:1||Genderdependent association:1||Gestational diabetes:1||Gestational diabetes mellitus:1||Ginsenoside Mc1:1||Glucagonlike peptide1 receptor agonist:1||Glucose Intolerance:1||Glycaemic variability:1||Glycated hemoglobin A:1||Glycosaminoglycan:1||Gonadal agenesis:1||Gout:1||Graves disease:1||Graves&apos:1||Gray matter:1||HDL:1||HEPATIC STEATOSIS:1||

STATISTICS: Total View :7,654,597; Today View :8,360

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841) 82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE